OOIR: Observatory of International Research

Papers

(The TQCC of Drug Metabolism and Pharmacokinetics is 1. The table below lists those papers that are above that threshold based on CrossRef citation counts [max. 250 papers]. The publications cover those that have been published in the past four years, i.e., from 2021-05-01 to 2025-05-01.)

Article	Citations
Prediction and validation of fetal exposure to dual BCRP/P-GP drug substrates using the proteomics informed efflux ratio-relative expression factor (ER-REF) approach and PBPK modeling and simulation	184
Corrigendum to “Utility of Göttingen minipigs for the prediction of human pharmacokinetic profiles after intravenous drug administration” [Drug Metabol Pharmacokinet 41 (2021) 100408]	102
Effects of genetic polymorphisms of canine CYP2D15 on in vitro hepatic metabolism and in vivo pharmacokinetics of celecoxib, and the strategy for the accurate prediction of human pharmacokinetics	61
Monocarboxylate transporter 10: substrate-dependent mode of transport	24
The spectrum of hepatic clearance models, from old to new	24
Development of an in vitro metabolism approach of acrylamide covalent drugs for predicting metabolism and disposition in human	22
Beyond non-human primates: Transgenics and PBPK models for predicting the human PK of protein therapeutics	15
The mass balance recovery, absorption, metabolism, and excretion of [14C]-orvepitant in healthy male subjects after oral dosing: radiosynthesis of [14c]-orvepitant	15
Clinical studies on pharmacogenomics and DDIS involving drug transporters	15
Formation of reactive metabolites of benzbromarone in humanized-liver mice	14
Development of a new assay system for bladder cancer using interactions between cytochromes P450 and serum	14
Dual kinetics of OATP2B1: Inhibitory potency and pH-dependence of OATP2B1 inhibitors	13
In vitro demonstration of antedrug mechanism of a pharmacokinetic booster to improve CYP3A4 substrates by CYP3A4-mediated metabolism inhibition	12
Applications of model simulation in pharmacological fields and the problems of theoretical reliability	12
Double Trap Interface: A novel gas interface for high throughput analysis of biomedical samples by AMS	12
Pharmacokinetics of ginsenosides and effect of the lactic acid bacteria on pharmacokinetics of ginsenosides in mice and human	11
Lysosomal trapping measurement in multiple cell types using a high content imaging (HCI) system	11
Human liver chimeric mouse and trasngenic animals are useful tools for quantitatively predicting clearance and drug-drug interactions in human	11
Strategies for enhancing oral exposure of water-insoluble compounds	10
Effect of antibiotic-administration period on hepatic bile acid profile and expression of pharmacokinetic-related proteins in mouse liver, kidney, and brain capillaries	9
Physiologically based pharmacokinetic modeling to predict the clinical effect of azole antifungal agents as CYP3A inhibitors on azelnidipine pharmacokinetics	9
Mathematical modeling of affinity design goals for CIS-binding BI-specific antibody-based molecules	8
Effect of linker-payload design on the PK of ADCS	8
Gene and Oligonucleotide Delivery	8
Enzyme induction fundamentals, assays, data interpretation and in vivo translation	8

Appreciation to Reviewers	8
In vitro and in vivo interactions between nicotine and the cannabis terpene limonene	8
Strategies for de-risking n-nitrosamine impurities in APIS	7
Suppression and induction of UGT by rhein and alvocidib in intestinal epithelial cells	7
This is no longer just about liver: LC-MS proteomics for organ exposure brain/kidney/gut/skin/placenta	7
Lecture title not available	7
Carboxylesterase-2 plays a critical role in dabigatran etexilate active metabolite formation	7
Clinical studies on pharmacogenomics and DDIS involving drug transporters	7
Pharmacokinetic interaction of caffeine and theophylline in mice	7
IN VITRO AND IN VIVO SYSTEMS FOR PREDICTING THE ADME OF PROTEIN THERAPEUTICS: ARE WE THERE YET?”	6
Simple confirmation methods for rare but impaired variants of human flavin-containing monooxygenase 3 (FMO3) found in an updated genome resource databank	6
Development of physiologically-based pharmacokinetic models to predict food effects and co-administration of proton pump inhibitors on the pharmacokinetics of sonidegib and vismodegib	6
Use of mathematical modeling to guide out-of-the-box thinking for ADC development	6
Cloning, sequence analysis, and tissue expression of marmoset paraoxonase 1	6
Exposure to mixed microplastic particles altered the fecal microbiome and its associated predictive functional pathways in mice	6
Disposition of E-selectin-targeting liposomes in tumor spheroids with a perfusable vascular network	6
A workflow for oligonucleotide metabolite identification studies	6
Effect of pregnancy-related hormones on mRNA expression of hepatic drug transporters and enzymes	6
Prediction of drug-drug interaction risk of P-glycoprotein substrate in drug discovery	5
Opportunities for microphysiological systems from the view of Japanese industries	5
Micro-physiological system of human lung: The current status and application to drug discovery	5
Mechanisms of afatinib-induced intestinal epithelial barrier dysfunction using human mini-gut model	5
Development of fluorescent-labeled trapping reagents based on cysteine to detect soft and hard electrophilic reactive metabolites	5
Intestinal microbiota-mediated biotransformations alter the pharmacokinetics of the major metabolites of azathioprine in rats after oral administration	5
Interactions of sutezolid and its active metabolite with human transporters	5
Prediction of pharmacokinetics and pharmacodynamics in human for IRAK4 targeted protein degrader	5
Spatial mapping of gemcitabine and its pharmacologically active metabolites in tissues using MALDI mass spectrometry imaging	5
The effect of clofazimine in modulating intracellular concentrations of remdesivir and GS-441524: A potential mechanism of enhancing antiviral effects against SARS-COV-2	5
Oligonucleotide delivery to antigen presenting cells by using schizophyllan	5
Therapeutic application of sequence-specific binding molecules for novel genome editing tools	5
Impact of donor diversity on phase I and phase II activities in cryopreserved human hepatocytes and human liver microsomes	5
Corrigendum to “Establishment of human intestinal organoids derived from commercially available cryopreserved intestinal epithelium and evaluation for pharmacokinetic study” [Drug Metabol Pharmacokine	5
OCT1 transporter kinetics and long-term modulation studies in 3D cultured primary human hepatocytes	5
Insights into drug development with quantitative systems pharmacology: A prospective case study of uncovering hyperkalemia risk in diabetic nephropathy with virtual clinical trials	5
Experimental validation of the reliability of dilution method for plasma protein binding assay in human plasma using 12 commercial compounds	4
Use of human liver microsomes to assess flavin-containing monooxygenase (FMO) metabolism in vitro	4
Epicatechin gallate and epigallocatechin gallate are potent inhibitors of human arylacetamide deacetylase	4
Beyond the basics: A deep dive into parameter estimation for advanced PBPK and QSP models	4
Evaluation of OSTΑ/Β transporter activity on the basal membrane of CACO-2 cell monolayers	4
Substrate-dependent characteristics in the transport function of SLC19A3: examination of the aspect of its sensitivity to flavonoids	4
Increasing the therapeutic index of ADCs with payload binding selectivity enhancers	4
In vitro metabolic stability and in vivo phaarmacokinetic behavior of panobinostat in mouse models for the treatment of CNS tumors	4
Effects of valproate, an HDAC inhibitor, on the expression of folate carriers and folate metabolism-related genes in the placenta of rats	4
Metabolism of non-steroidal anti-inflammatory drugs (NSAIDs) by Streptomyces griseolus CYP105A1 and its variants	4
Evaluating the impact of glycocalyx on partitioning and distribution of basic drugs	4
Comparison on metabolic fate of dendrobium polysaccharides in gut microbiota fermentation process between healty and diabetic status	4
Promiscuity and quantitative contribution of UGT2B17 in drug and steroid metabolism determined by experimental and computational approaches	4
Comparative analysis of microcystin toxicity in 2D and 3D cultured primary human hepatocytes	4
Plausible drug interaction between cyclophosphamide and voriconazole via inhibition of CYP2B6	4
Utility of Göttingen minipigs for the prediction of human pharmacokinetic profiles after intravenous drug administration	4

Acetaminophen-induced liver injury and the microbiome	4
ADME: 14C-RLY-4008 following oral administration to rats	4
Assessing complex drug-drug interactions using the truvivotm hepatocyte model	4
Species differences between rats and primates (humans and monkeys) in complex cleavage pathways of DS-8500a characterized by 14C-ADME studies in humans and monkeys after administration of two radiolab	3
Jasmone, an essential oil component, is an antagonist of aryl hydrocarbon receptor in liver and intestinal cells	3
Preclinical evaluation of the potential for cytochrome P450 inhibition and induction by tucatinib	3
The effect of traditional herbal medicine on the permeability of clarithromycin and loxoprofen in CACO-2 cell model	3
The practical impact of the FDA draft guidance on human mass balance studies – a year of client discussions	3
Clinical evaluation of [18F]pitavastatin for quantitative analysis of hepatobiliary transporter activity	3
Unveiling the intracellular journey: GOLGA8N-mediated subcellular trafficking of siRNA drugs and its implications on silencing efficacy	3
A practical approach for measuring acyl glucuronide migration half life	3
Verification of a physiologically based pharmacokinetic model of caffeine that incorporates mechanistic descriptors of absorption	3
Synthetic mRNA for ex vivo therapeutic applications	3
Evaluation of a novel, primary human hepatocyte tri-culture model, truvivotm, for its ability to predict metabolic clearance of CYP, UGT, and AO substrates	3
Drug transporters are implicated in the diffusion of tacrolimus into the T lymphocyte in kidney and liver transplant recipients: Genetic, mRNA, protein expression, and functionality	3
Stereoisomer separation of drugs and biomarkers using supercritical fluid chromatography to support PK/PD studies	3
Exploration of bioactivation of a branched-chain ketoacid dehydrogenase kinase (BDK) inhibitor	3
Population pharmacokinetic modeling of treosulfan and rationale for dose recommendation in children treated for conditioning prior to allogeneic hematopoietic stem cell transplantation	2
Pharmacokinetic properties of a truncated milk fat globule-EGF-like factor 8 in rats	2
Elucidate the metabolism of lipidated serotonin and selected drugs by cytochrome P450 2U1 (CYP2U1) in nanodiscs	2
Genetic variants of flavin-containing monooxygenase 3 (FMO3) in Japanese subjects identified by phenotyping for trimethylaminuria and found in a database of genome resources	2
Involvement of multiple cytochrome P450 isoenzymes in drug interactions between ritonavir and direct oral anticoagulants	2
Transporter or membrane barriers effects on hepatic clearance (the extended clearance equation) models and the need for scaling for IVIVE	2
CYP and UGT inhibition to assess perpetrator drug-drug interaction potential	2
Reduced theophylline clearance due to hepatic congestion secondary to right heart failure - A population pharmacokinetic study	2
Development and application of 3D cardiac tissues derived from human pluripotent stem cells	2
What is the role of CYP1A1 in drug metabolism?	2
ADME considerations from FIH to drug approval	2
Imaging Mass Spectrometry (IMS) for drug discovery and development survey: Results on methods, applications and regulatory compliance	2
Microbiome impacts on drug metabolism	2
Ferulic acid prevents Diosbulbin B-induced liver injury by inhibiting covalent modifications on proteins	2
OATP1B-mediated hepatic uptake of low-molecular weight acid compounds: assessment of HIF prolyl-hydroxylase inhibitors (DUSTATS)	2
Synthetic molecule libraries for nucleic acid delivery: Design parameters in cationic/ionizable lipids and polymers	2
Understanding CYP3A4 and P-GP mediated drug-drug interactions through PBPK modeling - case example of pralsetinib	2
Development of template systems for ligand interactions of CYP3A5 and CYP3A7 and their distinctions from CYP3A4 template	2
Adenovirus vector-based vaccine for infectious diseases	2
Establishment and characterization of an in vitro model for NTCP substrate and inhibition assessment	2
For hepatically cleared drugs, liver to blood KPUU at steady-state is always equal to FH , which exposes the deficiency of the present extended clearance concept equation	1
Impact of P-glycoprotein on intracellular drug concentration in peripheral blood mononuclear cells and K562 cells	1
CYP46A1 inhibition and activation: an in vitro high throughput screening assay to assess possible drug interactions using FDA approved chemical library	1
Organoids and microphysiological systems for pharmaceutical research of viral respiratory infections	1
Downregulated expression of organic anion transporting polypeptide (Oatp) 2b1 in the small intestine of rats with acute kidney injury	1
Challenges associated with the biomarker-informed PBPK modeling of renal transporter-mediated drug interactions	1
Predicting drug metabolism and pharmacokinetics features of in-house compounds by a hybrid machine-learning model	1
LC-MS for identifying changes (or lack of it) in ADME across different cohorts	1
Cross-species drug metabolism and impact of metabolic stability testing under anaerobic condition on predicting pharmacokinetics of keto-enol containing compound in humans	1
Oxidative metabolism and pharmacokinetics of the EGFR inhibitor BIBX1382 in chimeric NOG-TKm30 mice transplanted with human hepatocytes	1
P-GP limits rodent oral absoprtion of protacs	1
A family study of compound variants of flavin-containing monooxygenase 3 (FMO3) in Japanese subjects found by urinary phenotyping for trimethylaminuria	1
Metabolic pathways of aschantin in human liver preparations	1
An improved TK-NOG mouse as a novel platform for humanized liver that overcomes limitations in both male and female animals	1
Endosomal escape for intracellular delivery of RNA therapeutics: current and future strategies	1
Novel coc-based liver tissue chip for predictive pharmacokinetic and toxicology applications	1
Difference in the lipid nanoparticle technology employed in three approved siRNA (Patisiran) and mRNA (COVID-19 vaccine) drugs	1
Establishment of human intestinal organoids derived from commercially available cryopreserved intestinal epithelium and evaluation for pharmacokinetic study	1
Characterization of LysoTracker Red uptake by in vitro model cells of the outer blood-retinal barrier: Implication of lysosomal trapping with cytoplasmic vacuolation and cytotoxicity	1
Quantitative proteomics identifies significant changes in the abundance and composition of hepatic drug metabolizing enzymes in heavy alcohol drinkers	1
Physiologically based pharmacokinetic (PBPK) model that describes enhanced FcRn-dependent distribution of monoclonal antibodies (mAbs) by pI-engineering in mice	1
Validation of a modified in situ perfusion model for measuring drug intestinal excretion and evaluation of the drug-drug interactions in the intestine by I.V. administration	1
Population pharmacokinetics of blonanserin in Japanese adolescent and adult patients with schizophrenia	1
Evaluation and prediction of oral drug absorption and bioequivalence with food-druginteraction	1
Drug metabolism by the human gut microbiome	1
Translational PK/PD of the targeted radioligand therapy pluvicto	1
Liver targeted therapy: What mist and DDI data mean for efficacy	1
Comparison of the transport kinetics of fexofenadine and its pH dependency among OATP1A2 genetic variants	1
Bringing totality-of-evidence into PBPK predictions: fraction metabolised by aldehyde oxidase	1